Pancreatic Cancer Research

ResearcherUniversitair Ziekenhuis LeuvenNo recent work listed

Chris Verslype

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3857-466X; OpenAlex author ID A5001010553. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper

Papers 8

  1. Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A … Last author DOI 10.1186/s12967-023-04145-z↗
  2. Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2020.01.004↗
  3. Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts. Co-author PMID 30899378↗
  4. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. Co-author DOI 10.1002/ijc.31603↗
  5. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
  6. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  7. Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature. Co-author DOI 10.1111/ijd.14067↗
  8. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. First author DOI 10.1093/annonc/mdr351↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eric Van Cutsem · 7 shared papers, 2018–2023 · strength 0.68
  2. Jos F. van Pelt · 3 shared papers, 2019–2023 · strength 0.40
  3. Ashenafi Shiferaw Bulle · 2 shared papers, 2019–2020 · strength 0.20
  4. Jeroen Dekervel · 2 shared papers, 2019–2020 · strength 0.20
  5. Teresa Mercade Macarulla · 3 shared papers, 2018 · strength 0.19
  6. Manuel M. Hidalgo · 2 shared papers, 2018 · strength 0.14
  7. Eileen Mary O'Reilly · 2 shared papers, 2018 · strength 0.12
  8. Rekin’s Janky · 1 shared paper, 2020 · strength 0.10
  9. Baki Topal · 1 shared paper, 2020 · strength 0.10
  10. Pascal R. Hammel · 2 shared papers, 2012–2018 · strength 0.09
  11. Lien Verhulst · 1 shared paper, 2018 · strength 0.09
  12. Petra De Haes · 1 shared paper, 2018 · strength 0.09
  13. Thierry Conroy · 2 shared papers, 2012–2018 · strength 0.08
  14. Jean‐Luc Van Laethem · 2 shared papers, 2012–2018 · strength 0.08
  15. John P. Neoptolemos · 2 shared papers, 2012–2018 · strength 0.08
  16. Nebojsa S. Manojlovic · 1 shared paper, 2018 · strength 0.07
  17. Dejan V. Radenkovic · 1 shared paper, 2018 · strength 0.07
  18. Antonio Cubillo · 1 shared paper, 2018 · strength 0.07
  19. Éric Raymond · 1 shared paper, 2018 · strength 0.07
  20. Fitzroy Dawkins · 1 shared paper, 2018 · strength 0.07
  21. Ashwin Reddy Sama · 1 shared paper, 2018 · strength 0.07
  22. Herbert I. Hurwitz · 1 shared paper, 2018 · strength 0.07
  23. Chung‐Pin Li · 1 shared paper, 2018 · strength 0.07
  24. Edward W. Greeno · 1 shared paper, 2018 · strength 0.07
  25. Vaibhav Sahai · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.